05:23 PM EDT, 05/23/2024 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) said data from an interim analysis of a phase 2a study of SPN-817 demonstrated "strong evidence" of clinical utility in epilepsy.

The study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, while finding effective doses in various treatment-resistant seizure types, the company said late Thursday.

The company said the interim analysis comes from 41 enrolled subjects, of which 19 completed the maintenance period.

The company said interim data showed a 75% median focal seizure reduction on 3 to 4-milligram twice-daily doses during the so-called maintenance period.

It reported 86% median focal seizure reduction on 3 to 4-milligram twice-daily doses in the open-label extension period.

"In addition, the data provide important insights for the design of the upcoming phase 2b clinical study that we plan on initiating before year end 2024," said Jack Khattar, Chief Executive of Supernus.